Celcuity Short Interest Rises to 31.8%
Welcome to this week's installment of "The Short Interest Report" - The Fly's weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the data from our partnerwhich utilizes the latest information from stock lenders to estimate short interest changes for thousands of publicly traded companies, this report will screen for some of biggest changes in short interest as a percentage of free float and days-to-cover ratios while also considering the short interest data on some of the more volatile and heavier-traded names of the week. Based on the availability of data from Ortex, the report tracks the trading period that covers prior Friday through Thursday of this week, excluding holidays. As a basis of comparison for stocks discussed below, the S&P 500 index was down 0.5%, the Nasdaq Composite was down 0.4%, the Russell 2000 index was up 1.7%, the Russell 2000 Growth ETFwas up 1.6%, and the Russell 2000 Value ETFwas up 1.8% in the four-day trading session range through January 22.SHORT INTEREST GAINERSAs profiled last week, Ortex-reported short interest on Celcuityhad troughed at a three-month low below 20% in the final week of November, followed by a gradual ascend that picked up speed in the first half of January. The bears demonstrated greater resolve as the percentage of short interest to free float had jumped from 23.7% to 28.8% last week, and this week, the trend continued, with short interest gaining another three percentage points to 31.8% - now less than two points away from 2025 highs just north of 33%. With trading volume holding steady, days-to-cover on the name also continued to climb, rising from 5.0 to 6.0. The stock, meanwhile, was up 5.2% in the four-day period covered through Thursday and has now gained 10.3% year-to-date.Ortex-reported short interest on Intuitive Machineshad tracked in the 20%-23% range from the first week of December just beyond the half-way point of January, though this week has seen a spike in short positioning from 23.0% all the way above 28% - the highest level since September of 2024. Days-to-cover on the name is down notably however, slipping from 5.0 to 4.6 amid a more pronounced period of trading volume activity since mid-December. The stock has nearly tripled since its mid-November lows, rising from $8 per share to over $22, though while the bears were initially prone to reduce exposure, shorts are increasingly re-establishing positions in the new year. This week, Intuitive Machines shares were up another 5.7% in the four-day period covered, with year-to-date gain now seen at 23%.SHORT INTEREST DECLINERSOrtex-reported short interest on Redwirepeaked around 31% in the first week of January as bears looked to fade the 40% advance in the first few days of the new year, but as shares continued to climb, exuberance on the short side gave way to caution. This week, short positioning as a percentage of free float for Redwire fell from 26.4% to 21.8% - the lowest level since mid-November. Days to cover also scaled back to 3.2 from 3.8, even with trading volumes on the stock remaining well above normal ranges. The stock, meanwhile, picked up another 10% in the four-day period through Thursday and now stands having gained 18% from short interest peak on January 6th, 65% year-to-date, and 158% from mid-November lows.Ortex-reported short interest on Rezolve AIskyrocketed from 8% in the first week of December to an all-time high above 32% by mid-January as the stock also more than doubled in that timespan. With shares rolling over this week in conjunction with the company's announced $250M registered direct offering however, bears are also booking profits - short interest as a percentage of free float has declined from 32.3% all the way down to 21.3%, while days-to-cover on the name is down from 4.2 to 1.8. Rezolve AI has lost 25% in the four-day period covered and more than half of its value since the stock's peak in mid-September, though year-to-date in 2026, shares are still up 22%.
Trade with 70% Backtested Accuracy
Analyst Views on CELC
About CELC
About the author

- Indirect Share Sale: Director David Dalvey reported an indirect sale of 20,000 shares of Celcuity through Brightstone Venture Capital Fund for approximately $2.4 million, indicating a need for liquidity amid a strong stock performance.
- Holding Proportion Change: This transaction reduced Dalvey's indirect holdings from 110,000 to 90,000 shares, representing 18.18% of his total holdings, reflecting a trend of divestment in the company.
- Market Performance Review: Celcuity's stock has delivered a remarkable 933% total return over the past year, and Dalvey's sale occurs against this backdrop, potentially to lock in profits and manage future uncertainties.
- Trading Plan Context: The sale was executed under a Rule 10b5-1 trading plan adopted by Brightstone, indicating that Dalvey's transaction was prearranged to avoid insider trading implications, reminding investors to focus on the company's fundamentals rather than solely on insider trading activities.
- Biotech Summit Participation: Celcuity Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York, showcasing its latest advancements in oncology treatments and enhancing its visibility in the biotech industry.
- CEO Interview Schedule: CEO Brian Sullivan is set to engage in a fireside chat at 9:30 a.m. on February 11, where he is expected to discuss the company's strategic direction in targeted therapies, bolstering investor confidence in its growth trajectory.
- Clinical Trial Progress: Celcuity's lead therapeutic candidate, gedatolisib, is involved in multiple clinical trials, including VIKTORIA-1, which has completed enrollment, and VIKTORIA-2, which is currently enrolling, demonstrating the company's ongoing commitment and potential in cancer treatment.
- Unique Drug Mechanism: Gedatolisib, a potent pan-PI3K and mTORC1/2 inhibitor, has a mechanism of action that significantly differs from existing therapies, potentially offering new treatment options for various solid tumor patients and further solidifying the company's competitive position in the biopharmaceutical market.
- Disappointing Delivery Numbers: Xpeng Inc reported delivering 20,011 vehicles in January 2026, a figure that, while substantial, fell short of market expectations, leading to a decline in investor confidence.
- Stock Price Reaction: Following the disappointing delivery results, Xpeng's stock dropped 5.6% in pre-market trading to $16.97, reflecting concerns about the company's future performance among investors.
- Overall Market Trend: U.S. stock futures were lower, with Dow futures falling around 100 points, indicating a cautious market sentiment that could further impact investor attitudes towards Xpeng.
- Industry Impact: The delivery figures from Xpeng may negatively affect overall confidence in the electric vehicle market, especially in an increasingly competitive landscape, prompting investors to reassess their strategies.

- FDA Priority Review: Celcuity announced that its lead drug gedatolisib has received FDA priority review, marking a significant advancement in the biotech sector and potentially accelerating market entry.
- Target Approval Date: The FDA has set July 17, 2026, as the target action date for the new drug application for gedatolisib, providing a clear timeline for Celcuity's commercialization strategy.
- Clinical Trial Data Support: According to last month's data update, gedatolisib demonstrated a median progression-free survival of up to 12.4 months in the VIKTORIA-1 clinical trial, indicating its efficacy and favorable safety profile in combination therapy, thereby enhancing the likelihood of FDA approval.
- Revenue Potential Outlook: Celcuity outlines a peak revenue potential of $2.5 billion to $3 billion for gedatolisib, which is expected to attract more investor interest as the company accelerates its launch preparations.

- NDA Acceptance: Celcuity's New Drug Application for gedatolisib has been accepted by the FDA, targeting hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, showcasing the company's potential in oncology treatment.
- Priority Review Granted: The FDA has granted Priority Review status to the application, setting a goal date of July 17, 2026, indicating the agency's recognition of the drug's significance and potential market value.
- Clinical Trial Basis: The submission is based on data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial, demonstrating the drug's efficacy in clinical research and laying the groundwork for future market introduction.
- Market Reaction: Despite the positive FDA news, Celcuity shares fell over 2% in pre-market trading, reflecting cautious investor sentiment regarding the drug's market prospects, which may impact investor confidence.

- FDA Review Progress: Celcuity's New Drug Application for gedatolisib has been accepted for Priority Review by the FDA, with a PDUFA goal date of July 17, 2026, marking a significant milestone in providing a much-needed treatment option for patients with HR+/HER2- advanced breast cancer.
- Clinical Data Support: The application is based on clinical data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial, demonstrating gedatolisib's efficacy in inhibiting the PI3K/AKT/mTOR pathway, which could potentially change existing treatment paradigms and enhance market competitiveness.
- Multi-Target Mechanism Advantage: As a multi-target PI3K/AKT/mTOR inhibitor, gedatolisib offers comprehensive blockade of the PAM pathway, showing greater potency and cytotoxicity compared to single-target inhibitors, which may lead to improved clinical outcomes.
- Future Clinical Trial Plans: Celcuity is conducting multiple clinical trials, including VIKTORIA-2 and CELC-G-201, aimed at further validating the efficacy and safety of gedatolisib, which is expected to lay the groundwork for the company's future commercialization efforts.







